It would be intriguing to perform a structural analysis of such a compound and dissect its mechanism of action. An increasing amount of evidence suggests that eukaryotic 80S ribosome is a viable target for anti-cancer drugs (Prokhorova et al., 2016) . We believe that recent advances in cryo-EM and the X-ray structure of the Saccharomyces cerevisiae 80S ribosome (Garreau de Loubresse et al., 2014) , will make structural analysis of the R-IMPP mechanism of action and mode of binding feasible, and we expect that the structure of 80S ribosome bound to R-IMPP will be described in the near future, thus enabling further development of drugs for cardiovascular diseases.
The paper from Petersen et al. (2016) paves the way for the use of small molecule inhibitors targeting the 80S ribosome as an alternative therapeutic treatment of cardiovascular diseases and also for the specific effect of R-IMPP on the entire cell secretome.
In this issue of Cell Chemical Biology, Robbins et al. (2016) identify ibomycin, a unique compound with antifungal activity. Microbial physiological and genetic studies suggest that endocytic trafficking might be the site of action for this lead antifungal compound.
Microorganisms continuously compete with each other for survival in their environments. This can take the form of enhancing their own ability to acquire nutrients from the surroundings or developing rapid adaptation mechanisms to survive common environmental stresses such as fluctuations in temperature. In addition, many microorganisms produce substances that specifically inhibit the growth of neighboring species. For many years, individual investigators and pharmaceutical companies have taken advantage of this observation by screening microbial cultures for ''natural products,'' compounds that possess potent activity to kill other microorganisms, as a way to potentially combat human infectious diseases. Identifying these natural products has resulted in the development of most of our current antibiotics. Therefore, these types of studies are especially important in an era of increasing microbial resistance against many available antimicrobial agents. In addition, drugs derived from natural products are also extensively used for their immune There are many benefits to using a natural product-based approach to identify new antimicrobial agents (Roemer et al., 2011) . First, these compounds have been selected in nature for efficient cell penetration and for potency. Although many chemical compounds effectively inhibit specific microbial cell processes, not many compounds have the appropriate solubility or intracellular availability that would allow them to be considered as true drugs. However, natural product screens also have their limitations. Given nature's tendency toward parsimony, many of the compounds identified in such screens tend to fall into reproducible categories; finding truly novel compounds with new mechanisms of antimicrobial action is an increasingly rare event. Moreover, there is the issue of ''collateral damage.'' Substances that inhibit the growth of microorganisms, especially eukaryotic pathogens, might also have potent toxic effects against mammalian cells.
The manuscript by Robbins et al. (2016) in this issue of Cell Chemical Biology describes an innovative approach to identifying novel lead compounds for antifungal therapy. More than superficial nuisances of the skin, invasive fungal infections are increasingly common and life-threatening, mostly in patients with profound defects in immunity (Brown et al., 2012) . These at-risk populations include patients with various cancers who are being treated with chemotherapeutic agents. Other vulnerable populations include patients with transplants or autoimmune diseases in whom immunosuppressive therapy can be life-saving but also detrimental due to the inherent risks of secondary infections. In addition, although we are often able to effectively treat HIV infections, many patients throughout the world continue to experience the immune devastations of untreated AIDS due to insecure medication access or poor compliance with medical therapy. Therefore, species names such as Candida albicans, Cryptococcus neoformans, and Aspergillus fumigatus are increasingly recognized as causes of infectious disease on the clinical wards. The spectrum and number of available antifungal agents is exceedingly limited, and new drugs are needed to treat these serious infections.
In the past, natural product screens for antifungals have been hampered by the repeated identification of compounds of known and predictable classes, especially polyenes (Roemer et al., 2011) . To address this issue, the authors explored a unique collection of actinomycetes for natural products with specific antifungal activity. Actinomycetes are bacterial species that are rich sources of compounds with antimicrobial effects. These investigators developed a serial screening approach by first testing extracts of various Streptomyces isolates for antifungal activities, and second by limiting further investigations to those extracts that only inhibited a single fungal species, Cryptococcus neoformans. This approach was designed to avoid finding previously identified, non-specific antifungal compounds/classes, such as polyenes, that would be predicted to possess activity against many fungal species. This strategy was also specifically developed to find potent inhibitors of this particular fungus, a species that causes a devastating infection of the central nervous system that resuls in the death of hundreds of thousands of AIDS patients each year (Park et al., 2009) .
As reported by Robbins et al. (2016) , the authors first identified a crude Streptomyces bacterial extract with specific anti-Cryptococcus activity. They subsequently defined the compound ibomycin that is responsible for this antifungal activity. Ibomycin is a large type-I polyketide with a novel chemical structure. As expected for a compound identified from this type of screen, ibomycin was able to penetrate the target cell and potently inhibit its growth. It is of interest that many microbial secondary metabolites, such as ibomycin, are made by a sequential series of reactions catalyzed by enzymes whose genes are clustered in the genome and thereby transcriptionally co-regulated. After identifying the chemical nature of ibomycin, the authors used whole genome sequencing to identify the cluster of genes that is likely responsible for its synthesis.
In addition to finding a new antimicrobial compound, the authors used several methods to infer its mechanism of action. By testing this compound against a library of Saccharomyces cerevisiae strains with heterozygous mutations in most genes in the genome, they were able to identify membrane-associated signaling processes that seemed to operate in tandem with ibomycin. Further physiological experiments in yeast supported membrane fluidity and endocytic trafficking as likely targets of this compound.
Despite the elegance of these studies, the limitations of this type of screening approach include target specificity and the potential for ''collateral damage.'' In order to proceed with investigations for any potential antimicrobial agent, studies must first demonstrate that the compound is not excessively toxic against the host. This is especially true for antifungal compounds, given the striking cellular similarities between these eukaryotic microorganisms and their human and animal hosts. It is possible that this type of collateral toxicity will be minimized with this interesting screening approach, finding compounds that were not broadly toxic to all fungi, but merely to specific fungal species. Perhaps ibomycin's lack of broad antifungal effect will translate to less eukaryote-wide toxicity. In any event, given the exciting novelty of this newly identified compound, further toxicity and chemical optimization studies are clearly warranted.
